Tremfya Demonstrates Impressive Results Across Biologic-Naive and Biologic-Refractory Patients in Crohn's Disease and Ulcerative Colitis
October 11, 2024
October 11, 2024
NEW BRUNSWICK, New Jersey, Oct. 11 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
TREMFYA is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease
TREMFYA is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naive and biologic-refractory
Ninety percent more biologic-naive patients . . .
* * *
TREMFYA is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease
TREMFYA is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naive and biologic-refractory
Ninety percent more biologic-naive patients . . .